Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

What is Tilray Inc.?

Tilray Brands (TLRY) is a cannabis company operating globally, with a focus on medical cannabis and related products. The stock had a significant bearish movement today amidst various developments in the market.

Why is Tilray Inc. going down?

TLRY stock is down 5.2% on Jan 28, 2026 16:40

• Analyst downgrades and a significant earnings per share (EPS) miss contributed to a 3.6% drop in Tilray Brands' shares, leading to the stock trading below its key moving averages.
• Despite some institutional investment interest, the company reported a deeply negative net margin and is projected to have a negative EPS for the current year, impacting investor sentiment.
• The expansion of Tilray's European medical cannabis platform through Italy was seen as a positive move, but investors are still awaiting progress on U.S. medical cannabis reclassification and effective management of losses to mitigate risks.
• The launch of a new high-ABV beer by SweetWater Brewing Company, a subsidiary of Tilray Brands, did not seem to have a significant impact on the stock's bearish movement today.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands (NASDAQ:TLRY) Shares Down 3.6% - Here's What Happened

Tilray Brands (NASDAQ:TLRY) shares dropped 3.6% during mid-day trading following a period of analyst downgrades and a significant EPS miss in their latest earnings report. The company's stock is trading below its 50-day and 200-day moving averages, and analysts have a "Reduce" consensus rating with an average price target of $13.33. Despite some institutional investment, Tilray reported a deeply negative net margin and is forecasted to have a negative EPS for the current year.

https://www.marketbeat.com/instant-alerts/tilray-brands-nasdaqtlry-shares-down-36-heres-what-happened-2026-01-27/

Tilray Brands (TSE:TLRY) Given a C$13.00 Price Target by Canaccord Genuity Group Analysts

Canaccord Genuity Group analysts have issued a C$13.00 price target and a "hold" rating for Tilray Brands (TSE:TLRY), suggesting a 12.75% upside. This follows Sanford C. Bernstein's recent increase of their target to C$13.60, with the consensus price target among analysts being C$13.30 and a "Hold" rating. Tilray's shares are currently trading below their 50-day and 200-day moving averages, with a market capitalization of C$1.34 billion and a negative PE ratio of -0.49.

https://www.marketbeat.com/instant-alerts/tilray-brands-tsetlry-given-a-c1300-price-target-by-canaccord-genuity-group-analysts-2026-01-27/

SweetWater 420 Fest brings $40 tickets and Chromeo to Atlanta park

Tilray Brands' SweetWater Brewing Company announced the lineup and ticketing for the 21st annual SweetWater 420 Fest, taking place April 17-18, 2026, at Atlanta's Shirley Clarke Franklin Park. Headliners include Umphrey's McGee, Thievery Corporation, and Chromeo, with tickets starting at an affordable $40 for single-day general admission, a nearly 50% reduction from the previous year. The festival emphasizes a new, larger venue and accessible pricing to attract a broad audience.

https://www.stocktitan.net/news/TLRY/sweet-water-420-fest-unveils-powerhouse-2026-lineup-umphrey-s-mc-gee-w22km6n8ru3a.html

How Investors May Respond To Tilray Brands (TLRY) Expanding Its European Medical Cannabis Platform Through Italy

Tilray Brands (TLRY) is expanding its European medical cannabis platform by rebranding its Italian unit as Tilray Medical Italia and increasing its portfolio. This move supports Tilray's goal of building a unified global medical cannabis platform and aligns with recent record quarterly revenue from international sales. While the Italian expansion reinforces Tilray's focus on high-value medical markets, significant near-term catalysts for investors are still progress on U.S. medical cannabis reclassification and effectively managing losses, especially given past share price declines and dilution risks.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/how-investors-may-respond-to-tilray-brands-tlry-expanding-it

Stocks in play: Tilray Brands, Inc.

Tilray Brands, Inc. announced that its SweetWater Brewing Company has launched "Big Trip Double IPA," a new high-ABV beer with a 9% alcohol content, featuring citrus notes and a tropical aroma. Following this announcement, Tilray Brands, Inc. shares (T.TLRY) were trading up by $0.55 at $12.49.

https://www.barchart.com/story/news/37176378/stocks-in-play-tilray-brands-inc

Trending Today

Intel Corporation ($INTC) Stock Forecast: Up 10.3% Today

F5 Networks Inc. ($FFIV) Stock Forecast: Up 8.6% Today

Avantor, Inc. ($AVTR) Stock Forecast: Down 5.2% Today

Textron Inc. ($TXT) Stock Forecast: Down 8.5% Today

Sealed Air Corporation ($SEE) Stock Forecast: Up 0.2% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Up 7.5% Today

Corning Incorporated ($GLW) Stock Forecast: Down 5.7% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 8.7% Today

MSCI Inc ($MSCI) Stock Forecast: Up 5.2% Today

PACCAR Inc. ($PCAR) Stock Forecast: Up 5.5% Today

Tilray Inc. Price History

13.00.2026 - TLRY Stock was down 5.3%

• Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
• The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
• Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
• Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

22.11.2025 - TLRY Stock was down 6.0%

• The bearish movement in TLRY stock today could be attributed to the anticipation and uncertainty surrounding the upcoming financial results announcement.
• Comments on Tilray's lack of earnings may have contributed to investor skepticism and selling pressure on the stock.
• Despite the positive news about Tilray's formation of Tilray Medical USA, Inc. to advance its U.S. medical cannabis operations, the overall market sentiment may have been overshadowed by concerns about the company's financial performance and growth strategy.
• The market might be reacting to the realization that Tilray's growth is primarily driven by acquisitions in the alcohol sector rather than its struggling cannabis segment, raising doubts about the company's long-term sustainability.

22.00.2026 - TLRY Stock was up 5.1%

• TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
• The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
• Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
• The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

12.00.2026 - TLRY Stock was up 4.9%

• Reported a record Q2 Fiscal 2026 net revenue of $218 million, led by strong performance in international cannabis and Canadian adult-use cannabis segments.
• Transitioned to a net cash position and reaffirmed full-year Adjusted EBITDA guidance, highlighting disciplined execution and a strengthened balance sheet.
• Analysts' opinion that the recent share plunge was overdone aligns with financial results, suggesting potential undervaluation due to underestimation of profit growth in Canadian and international cannabis markets.
• Strategic expansion into the beverage segment, along with readiness to leverage medical cannabis infrastructure in the U.S., positions the company for future growth amidst potential regulatory shifts in the cannabis market.

16.00.2026 - TLRY Stock was down 5.1%

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

15.00.2026 - TLRY Stock was up 5.3%

• Tilray reported record Q2 revenues of $218 million, driven by international operations and distribution, showcasing the company's ability to capture market opportunities.
• Despite a recent EPS miss and negative net margins, the stock saw an increase as investors may be optimistic about the company's long-term growth prospects.
• The focus on higher-margin international markets and new THC beverage offerings indicates Tilray's commitment to diversification and sustainable profitability, which could have positively influenced investor sentiment.
• Analysts suggesting to consider other stocks for better investment opportunities may have created some uncertainty, but the overall market movement reflects confidence in Tilray's strategic direction and potential for future growth.

24.11.2025 - TLRY Stock was down 5.3%

• The upcoming announcement of Tilray Brands' second fiscal quarter financial results has likely created uncertainty and caution among investors, leading to a sell-off of the stock.
• Despite the recent drop, the stock has shown a notable increase over the past month, indicating potential profit-taking by traders.
• The lack of substantial analysis suggests a disconnect between market sentiment and speculative opinions on whether the stock's fall presents a buying opportunity.
• Investors are eagerly awaiting the earnings report, with expectations of a significant increase in EPS, but a slight decrease in revenue compared to the previous year, adding to the volatility surrounding the stock.

06.00.2026 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today can be attributed to multiple factors:
• The formation of a bearish head-and-shoulders pattern, indicating a potential trend reversal and investor caution.
• Heightened volatility ahead of the earnings release, with analysts expecting significant price swings and a projected loss per share.
• The company's expansion into non-alcoholic, cannabis-infused beverages for its "Dry January" campaign might not have been well-received by investors, impacting the stock negatively.
• Investors are closely monitoring Tilray's financial results release on January 9th, potential cannabis reclassification efforts in the US, and the impact of increased competition in the US market for further insights into the stock's performance.

28.00.2026 - TLRY Stock was down 5.2%

• Analyst downgrades and a significant earnings per share (EPS) miss contributed to a 3.6% drop in Tilray Brands' shares, leading to the stock trading below its key moving averages.
• Despite some institutional investment interest, the company reported a deeply negative net margin and is projected to have a negative EPS for the current year, impacting investor sentiment.
• The expansion of Tilray's European medical cannabis platform through Italy was seen as a positive move, but investors are still awaiting progress on U.S. medical cannabis reclassification and effective management of losses to mitigate risks.
• The launch of a new high-ABV beer by SweetWater Brewing Company, a subsidiary of Tilray Brands, did not seem to have a significant impact on the stock's bearish movement today.

02.00.2026 - TLRY Stock was up 5.6%

• Tilray's stock is struggling to maintain momentum despite recent U.S. regulatory shifts and political support, trading below key technical levels.
• Investor focus is on the upcoming Q2 earnings report, with expectations of a loss per share on revenue. Analysts are looking for signs of financial progress from cost-saving measures and brand integrations.
• The stock's increased attention on social media platforms is sparking discussions about whether TLRY's current mid-single digit trading price reflects a genuine recovery or speculative hype.
• Analysts have a cautiously optimistic stance, considering potential U.S. policy changes and growth in Tilray's alcohol business, balanced against risks like weak cannabis sales and ongoing losses.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock price decreased by 4.2%, closing at $10.085, which was below the broader market performance.
• Analysts have given a consensus "Hold" rating with an average price target of $20, showing caution among investors.
• The drop in stock price may be linked to lower-than-expected performance and uncertainties about the upcoming second fiscal quarter results.
• Despite optimistic prospects for potential cannabis rescheduling and hemp-derived products, investors might be hesitant due to recent underperformance and competition in the AI sector.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock experienced a 4.2% decline in value during mid-day trading, closing at $10.085.
• Analysts have assigned a consensus "Hold" rating to Tilray, with a median price target of $20, indicating a potential upside of 88.49%.
• The bearish movement could be attributed to the cautious sentiment among analysts, despite potential positive developments such as cannabis rescheduling and revised product definitions.
• The upcoming announcement of Tilray's second fiscal quarter results may also be contributing to investor uncertainty and selling pressure on the stock.